 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
- | ALN-AAT02 / Alnylam, Novo Nordisk
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Sep 16, 2020
P1/2, N=32, Terminated, Sponsor: Alnylam Pharmaceuticals
N=96 --> 32 | Trial completion date: Jun 2021 --> Jun 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2021 --> Jun 2020; The sponsor decided not to proceed with Part B for business reasons.
- | ALN-AAT02 / Alnylam, Novo Nordisk
Enrollment closed: A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Aug 7, 2019
P1/2, N=96, Active, not recruiting, Sponsor: Alnylam Pharmaceuticals
N=96 --> 32 | Trial completion date: Jun 2021 --> Jun 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2021 --> Jun 2020; The sponsor decided not to proceed with Part B for business reasons. Recruiting --> Active, not recruiting
- ||| ALN-AAT02 / Alnylam, Novo Nordisk
Enrollment open: A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Jan 10, 2019
P1/2, N=96, Recruiting, Sponsor: Alnylam Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| ALN-AAT02 / Alnylam, Novo Nordisk
New P1/2 trial: A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Dec 7, 2018
P1/2, N=96, Not yet recruiting, Sponsor: Alnylam Pharmaceuticals